

How COVID-19 is Accelerating the Digital Revolution pp 147–164

Treatment of Novel Coronavirus (2019-nCoV) Using Hinokitiol (β-thujaplicin) Copper Chelate

R. Anandan, Noor Zaman Jhanjhi & B. S. Deepak

Chapter | First Online: 19 May 2022

Abstract

Human Coronavirus (HCoV) or Novel Coronavirus (2019-nCoV) is probably a brand new version of coronavirus that belongs to Betacoronaviruses kind Human Coronaviruses, similar to the Severe Acute Respiratory Syndrome (SARS) coronavirus and Middle-East Respiratory Syndrome (MERS) coronavirus. China recorded the number one case of this virus in December 2019 at Wuhan, the capital town of

Hubei province. By 27 March 2020, 10:00 CET, nearly 23,335 humans died out of 509,164 showed instances recorded throughout the world. By the give up of January 2020, China showed that the Novel Coronavirus (2019-nCoV) transmitted from one human to another. This studies pursuits to research a completely specific medicament called "Hinokitiol Copper Chelate" towards the large quantity 2019-nCoV Spike Glycoprotein with a unmarried receptor binding domain. This take a look at gives a super version for Hinokitiol Copper Chelate to be examined in silico towards 2019-nCoV Main Protease.

Keywords

Hinokitiol Copper Chelate **COVID-19** **2019-nCoV**

Human coronavirus

References

1. Anthony, S. J., Epstein, J. H., Murray, K. A., Navarrete-Macias, I., Zambrana-Torrelio, C. M., et al. (2013a). A strategy to estimate unknown viral diversity in mammals. *MBio, 4*, e00598–e00513.

2. Bono, L. M., Gensel, C. L., Pfennig, D. W., & Burch, C. L. (2012). Competition and the origins of novelty: Experimental evolution of niche-width expansion in a virus. *Biology Letters, 9*, 20120616.

3. Bromham, L., & Penny, D. (2003). The modern molecular clock. *Nature Reviews Genetics, 4*, 216–224.

4. Bull, J. J., Meyers, L. A., & Lachmann, M. (2005). Quasispecies made simple. *PLoS Computational Biology, 1*, e61.

5. Bull, J. J., Sanjuan, R., & Wilke, C. O. (2007). Theory of lethal mutagenesis for viruses. *Journal of Virology, 81*, 2930–2939.

6. Bull, R. A., Eden, J. S., Rawlinson, W. D., & White, P. A. (2010). Rapid evolution of pandemic noroviruses of the GII.4 lineage. *PLoS Pathogens, 6*, e1000831.

7. Chow, S. S., Wilke, C. O., Ofria, C., Lenski, R. E., & Adami, C. (2004). Adaptive radiation from resource competition in digital organisms. *Science, 305*, 84–86.

8. Coronavirus disease 2019 (COVID-19) Situation report – 67. Retrieved March 29, 2020 from https://www.who.int/docs/default-

source/coronaviruse/situation-reports/20200327-sitrep-67-covid-19.pdf?sfvrsn=b65f68eb_4

9. Miyamoto, D., Kusagaya, Y., Endo, N., Sometani, A., Takeo, S., Suzuki, T., Arima, Y., Nakajima, K., & Suzuk, Y. (1998). Thujaplicin–copper chelates inhibit replication of human influenza viruses. *Antiviral Research, 39*(2), 89–100.

10. Daszak, P., Cunningham, A. A., & Hyatt, A. D. (2000). Emerging infectious disease of wildlife – Threates to biodiversity and human health. *Science, 287*, 443–449.

11. Docking (Molecular). (n.d.). In *Wikipedia*. Retrieved March 29, 2020, from https://en.wikipedia.org/wiki/Docking_(molecular)

12. Drake, J. W. (1993). Rates of spontaneous mutation among RNA viruses. *Proceedings of the National Academy of Sciences, 90*, 4171–4175.

13. Eigen, M. (1993). Viral quasispecies. *Scientific American, 269*, 42–49.

14. Elfiky, A. (2020). Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. *Life Sciences, 248*, 117477.

15. Erles, K., Toomey, C., Brooks, H. W., & Brownlie, J. (2003). Detection of a group 2 coronavirus in dogs with canine infectious respiratory disease. *Virology Journal, 310*, 216–223.

16. Gao, F., Bailes, E., Robertson, D. L., Chen, Y., Rodenburg, C. M., Michael, S. F., Cummins, L. B., Arthur, L. O., Martine, P., Shaw, G. M., Sharp, P. M., & Hahn, B. H. (1999). Origin of HIV-1 in the chimpanzee *Pan troglodytes troglodytes*. *Nature, 397*, 436–441.

17. Gierer, S., Bertram, S., Kaup, F., Wrensch, F.,

Heurich, A., et al. (2013). The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. *Journal of Virology, 87*, 5502–5511.

18. Gojobori, T., Moriyama, E. N., & Kimura, M. (1990). Molecular clock of viral evolution and the neutral theory. *Proceedings of the National Academy of Sciences, 87*, 10015–10018.

19. Graham, R. L., Becker, M. M., Eckerle, L. D., Bolles, M., Denison, M. R., & Baric, R. S. (2012). A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. *Nature Medicine, 18*, 1820–1826.

20. Graham, R. L., Donaldson, E. F., & Baric, R. S. (2013). A decade after SARS: Strategies for

controlling emerging coronaviruses. *Nature Reviews. Microbiology, 11*, 836–848.

21. Hasoksuz, M., Alekseev, K., Vlasova, A., Zhang, X., Spiro, D., et al. (2007). Biologic, antigenic, and full-length genomic characterization of a bovine-like coronavirus isolated from a giraffe. *Journal of Virology, 81*, 4981–4990.

22. Hayden, F., & Croisier, A. (2005). Transmission of avian influenza viruses to and between humans. *The Journal of Infectious Diseases, 192*, 1311–1314.

23. Holmes, E. C., & Rambaut, A. (2004). Viral evolution and the emergence of SARS coronavirus. *Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 359*, 1059–1065.

24. Holmes, K. V. (2003). SARS-associated coronavirus. *The New*

England Journal of Medicine, 348, 1948–51 104.

25. Howard, C. R., & Fletcher, N. F. (2012). Emerging virus disease: Can we ever expect the unexpected? *Emerging Microbes and Infections, 1*, e46.

26. In silico. (n.d.). In *Wikipedia*. Retrieved March 29, 2020, from http://en.wikipedia.org/wiki/Psychology; https://en.wikipedia.org/wiki/In_silico

27. Jenkins, G. M., et al. (2002). Rates of molecular evolution in RNA viruses: A quantitative phylogenetic analysis. *Journal of Molecular Evolution, 54*, 156–165.

28. Sagripanti, J.-L., Routson, L. B., & Lytle, C. D. (1993). Virus inactivation by copper or iron ions alone and in the presence of peroxide. *Applied and Environmental Microbiology, 59*(12), 4374–4376.

29. Kimura, M. (1984). *The neutral theory of molecular evolution*. Cambridge University Press.

30. Kimura, M. (1991). The neutral theory of molecular evolution: A review of recent evidence. *Japanese Journal of Genetics, 66*, 367–386.

31. Leitner, T., & Albert, J. (1999). The molecular clock of HIV-1 unveiled through analysis of a known transmission history. *Proceedings of the National Academy of Sciences, 96*, 10752–10757.

32. Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., Choe, H., & Farzan, M. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. *Nature, 426*, 450–454.

33. Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., et al. (2005a). Bats are natural reservoirs of SARS-like coronaviruses. *Science, 310*, 676–679.

34. Li, W., Wong, S. K., Li, F., Kuhn, J. H., Huang, I. C., et al. (2006). Animal origins of the severe acute respiratory syndrome coronavirus: Insight from ACE2-S-protein interactions. *Journal of Virology, 80*, 4211–4219.

35. Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., Wong, S., Huang, I., Xu, K., Vasilieva, N., Murakami, A., He, Y., Marasco, W. A., Guan, Y., Choe, H., & Farzan, M. (2005b). Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. *EMBO Journal, 24*, 1634–1643.

36. Li, W. H., Tanimura, M., & Sharp, P. M. (1987). An evaluation of the molecular clock hypothesis using mammalian DNA sequences. *Journal of Molecular Evolution, 25*, 330–342.

37. Barret, M. C., Mahon, M. F., Molloy, K. C., Wright, P., & Creeth, J. E. (2002). The structural chemistry of copper(II) hinokitiol and its adducts. *Polyhedron, 21*(17), 1761–1766.

38. Nichol, S. T., Rowe, J. E., & Fitch, W. M. (1993). Punctuate equilibrium and positive Darwinian evolution in vesicular stomatitis virus. *Proceedings of the National Academy of Sciences of the United States of America, 90*, 10424–10428.

39. Perlman, S., & Netland, J. (2009). Coronaviruses post-SARS: Update on replication and pathogenesis. *Nature Reviews. Microbiology, 7*, 439–450.

40. Rainey, P. B., & Travisano, M. (1998). Adaptive radiation in a hetergenous environment. *Nature, 394*, 69–72.

41. Rupprecht, C. E., Hanlon, C. A., & Hemachudha, T. (2002). Rabies re-examined. *The Lancet Infectious Diseases, 2*, 327–343.

42. Sanjuan, R., Cuevas, J. M., Furio, V., Holmes, E. C., & Moya, A. (2007). Selection for robustness in mutagenized RNA viruses. *PLoS Genetics, 3*, e93.

43. Sanjuan, R., Moya, A., & Elena, S. F. (2004). The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. *Proceedings of the National Academy of Sciences of the United States of America, 101*, 8396–8401.

44. Sanjuan, R., Nebot, M. R., Chirico, N., Mansky, L. M., & Belshaw, R. (2010). Viral mutation rates. *Journal of Virology, 84*, 9733–9748.

45. Sanjuan, R. (2012). From molecular genetics to

phylodynamics: Evolutionary relevance of mutation rates across viruses. *PLoS Pathogens, 8*, e1002685.

46. Warnes, S. L., Little, Z. R., & Keevil, C. W. (2015). Human coronavirus 229E remains Infectious on common touch surface materials. *MBio, 6*(6), e01697-15.

47. Scull, M. A., Gillim-Ross, S. C., Roberts, K. L., Bordonali, E., Subbarao, K., Barclay, W. S., & Pickles, R. J. (2009). Avian influenza virus glycoproteins restrict virus replication and spread through human airway epithelium at temperatures of the proximal airways. *PLoS Pathogens, 5*, e1000424.

48. Shirato, K., Kawase, M., & Matsuyama, S. (2013). Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. *Journal of Virology, 87*, 12552–12561.

49. Suttle, C. A. (2007). Marine viruses – Major players in the global ecosystem. *Nature Reviews Microbiology, 5*, 801–812.

50. Taylor, L. H., Latham, S. M., & Woolhouse, M. E. J. (2001). Risk factors for human disease emergence. *Philosophical Transactions. Royal Society of London, 356*, 983–989.

51. Ishida, T. (2018). Antiviral activities of Cu2+ ions in viral prevention, replication, RNA degradation, and for antiviral efficacies of lytic virus, ROS-mediated virus, copper chelation. *World Scientific News, 99*, 148–168.

52. Wang, L. F., & Eaton, B. T. (2007). Bats, civets and the emergence of SARS. *Wildlife and Emerging Zoonotic Diseases: The Biology, Circumstances and Consequences of Cross-Species Transmission, 315*, 325–344.

53. Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D.,

et al. (2013). Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. *Cell Research, 23*, 986–993.

54. Wang, Q., Qi, J., Yuan, Y., Xuan, Y., Han, P., et al. (2014). Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. *Cell Host & Microbe, 16*, 328–337.

55. Wang, W., Lin, X. D., Guo, W. P., Zhou, R. H., Wang, M. R., et al. (2015). Discovery, diversity and evolution of novel coronaviruses sampled from rodents in China. *Virology, 474*, 19–27.

56. Woo, P. C. Y., Lau, S. K. P., Huang, Y., & Yuen, K. Y. (2009). Coronavirus diversity, phylogeny and interspecies jumping. *Experimental Biology and Medicine, 234*, 1117–1127.

57. Woolhouse, M. E. J., & Gowtage-Sequeria, S. (2005). Host range and emerging and reemerging pathogens. *Emerging Infectious Diseases, 11*, 1842–1847.

58. Woolhouse, M. E. J., Haydon, D. T., & Antia, R. (2005). Emerging pathogens: The epidemiology and evolution of species jumps. *Trends in Ecology & Evolution, 20*, 238–244.

59. Woolhouse, M. E. J. (2002). Population biology of emerging and re-emerging pathogens. *Trends in Microbiology, 10*, S3–S7.

Author information

Authors and Affiliations

Vels Institute of Science, Technology and Advanced Studies, Chennai, India

R. Anandan & B. S. Deepak

School of Computer Science (SCS), Taylor's University, Subang Jaya, Malaysia

Noor Zaman Jhanjhi

Corresponding author

Correspondence to R. Anandan .

Editor information

Editors and Affiliations

Vels Institute of Science, Technology and Advanced Studies, Chennai, India

Dr. R. Anandan

Department of Information Technology, Vels Institute of Science, Technology and Advanced Studies, Chennai, India

Dr. G. Suseendran

Department of CS, Tennessee State University, Nashville, TN, USA

Pushpita Chatterjee

School of Computer Science (SCS), Taylor's University, Selangor, Malaysia

Noor Zaman Jhanjhi

Department of CS&DS, School of Applied Computational Sciences Meharry Medical College, Nashville, TN, USA

Uttam Ghosh

Rights and permissions

Reprints and Permissions

Copyright information

About this chapter

Cite this chapter

Anandan, R., Jhanjhi, N.Z., Deepak, B.S. (2022). Treatment of Novel Coronavirus (2019-nCoV) Using Hinokitiol (β-thujaplicin) Copper Chelate. In: Anandan, R., Suseendran, G., Chatterjee, P., Jhanjhi, N.Z., Ghosh, U. (eds) How COVID-19 is Accelerating the Digital Revolution. Springer, Cham. https://doi.org/10.1007/978-3-030-98167-9_10

.RIS .ENW .BIB

DOI

https://doi.org/10.1007/978-3-030-98167-9_10

Published Publisher Name Print ISBN

19 May 2022 Springer, Cham 978-3-030-98166-2

Online ISBN eBook Packages

978-3-030-98167-9 Computer Science

Computer Science (R0)